Mortality by day 60Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: development of severe symptoms (≥ 7 WHO scale, IMV) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in admission to hospital or death by day 30Â compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
Quality of life · non‐hospitalised individuals with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 90 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in mortality by day 90 compared with placebo (low certainty).
1 finding from 1 review
Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease)
It is very uncertain whether bamlanivimab changes clinical progression: need for NIV, IMV, ECMO, or renal replacement… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to hospital discharge · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in time to hospital discharge up to 26.10.2020, absolute effects for… compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Hospital re‐admission within 30 days of discharge · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in admission to hospital by day 30 compared with placebo (low certainty).
1 finding from 1 review
 · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in  compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab may leads to lower mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review